P21

P021 is derived from the biologically active region of human CNTF, with an adamantylated glycine bolted onto the C-terminus to raise lipophilicity, resist exopeptidases and get it across the blood-brain barrier - it is orally active in rodents. Its proposed primary action is competitive inhibition of LIF signalling, which in CNTF biology suppresses the conversion of stem cells into neural progenitors; blocking it increases neurogenesis. Downstream, rodent studies report elevated BDNF and enhanced BDNF/CREB signalling, increased dentate gyrus neurogenesis, restored dendritic spine density, and reduced tau hyperphosphorylation via inhibition of GSK-3beta. In triple-transgenic Alzheimer mice chronic oral treatment improved cognition and reduced both tau and amyloid pathology.

Targets: Leukaemia inhibitory factor (LIF) signalling, BDNF/CREB pathway, GSK-3beta, Hippocampal neurogenesis

• · There is no human dose. Rodent studies used roughly 0.25-1 mg/kg daily; grey-market protocols land at 250-1000 mcg per day, which is a fraction of the allometric equivalent.
• · Used to bias delivery toward the brain and away from systemic exposure. No comparative data supports the route choice.

Work out your exact syringe units →

• commonInjection-site irritation
• uncommonHeadache
• uncommonFatigue or drowsiness
• rareUnknown long-term effects of chronic neurogenesis stimulation— Nobody has run this in a person for a year. The honest answer is that the side-effect profile is not characterised.

• Pregnancy and breastfeeding - no data.
• Active malignancy - a compound that manipulates progenitor-cell differentiation has not been evaluated in that setting.
• Do not use it as a substitute for evaluated treatment in diagnosed dementia.

• synergydihexa — Different neurotrophic mechanisms aimed at the same outcome; sometimes stacked, with zero data on the combination.
• redundantcerebrolysin — Cerebrolysin's claimed activity includes CNTF-like fragments, so the mechanisms substantially overlap.

• · No bloodwork established.
• · If you are using it for cognitive decline, get a real baseline - MoCA or a validated computerised battery - because self-assessment in that population is unreliable by definition.

Not approved anywhere; research chemical only.

• Kazim et al. 2014, disease-modifying effect of chronic oral P021 in a triple-transgenic Alzheimer's mouse model, Neurobiology of Disease (preclinical)
• Alzheimer's Drug Discovery Foundation Cognitive Vitality report on P021 (review)

The design logic of P021 is more interesting than the usual neurotrophic story and worth understanding because it explains why the compound is slow. CNTF biology contains a brake: leukaemia inhibitory factor signalling suppresses the conversion of neural stem cells into committed progenitors. P021 is proposed to competitively inhibit that LIF signalling, which does not push neurogenesis directly so much as release an existing restraint on it. That is a structurally different kind of intervention from Semax raising BDNF expression or FGL activating FGFR1, and it predicts exactly the timecourse the rodent studies show - nothing acute, benefits emerging over weeks to months of daily dosing, and outcomes that are structural rather than functional. Downstream, the reported effects converge on the same endpoints as the rest of this class: elevated BDNF with enhanced BDNF-CREB signalling, increased dentate gyrus neurogenesis, restored dendritic spine density, and reduced tau hyperphosphorylation via GSK-3beta inhibition. The tau arm is what made it an Alzheimer's candidate rather than a nootropic. The adamantyl cage deserves its own mention: it is the reason the compound works orally at all, and it makes P021 behave more like a lipophilic small molecule than a tetrapeptide, which is also why it is harder to dissolve than users expect.

The commonest failure is impatience. This is a compound whose rodent evidence came from months of continuous dosing, with outcomes that are structural - spine density, neurogenesis, tau burden - and none of which produce a subjective signal. People run it for three weeks, feel nothing, and conclude it is inert. That conclusion may be correct, but three weeks was never going to answer the question. The second problem is dissolution: the adamantyl group makes this considerably more lipophilic than a typical tetrapeptide, and it does not always go cleanly into bacteriostatic water. Warming the vial in your hand and swirling works; adding more water does not, and repeatedly agitating the vial to force it into solution damages the peptide. The third is the evidence gap people gloss over - P021 has been sitting at the preclinical stage for more than a decade with an intact, reasonably well-regarded rodent literature and has never entered a human trial. Compounds with genuinely strong preclinical data and a clear indication usually find a sponsor. That it has not is informative even though it is not conclusive.

1. 250 mcgWeek 1 — Once daily subcutaneous or intranasal. There is no human dose-response data, so the only rational approach is to start at the bottom of the anecdotal range and hold.
2. 500 mcgWeeks 2-4 — The middle of the grey-market range. Note that rodent efficacy came from roughly 0.25-1 mg/kg daily, which allometrically would be far more than this - the anecdotal human dosing is a small fraction of the animal-equivalent, not a multiple of it.
3. 1 mgWeeks 5-12 — Top of the anecdotal range. Because the mechanism is structural and slow, a course shorter than 8 weeks is unlikely to tell you anything either way - the rodent studies dosed for months before outcomes separated.

• Leukaemia inhibitory factor (LIF) signalling — Competitive inhibition proposed; no Ki has been published

  Releases the LIF-mediated brake on neural stem cell differentiation into progenitors. This is the proposed primary action and the reason the effect is slow and structural.

• BDNF / CREB pathway — Indirect - P021 raises BDNF expression rather than binding TrkB

  Enhanced BDNF-CREB signalling, increased dentate gyrus neurogenesis and restored dendritic spine density in rodent models.

• GSK-3beta — Not quantified as direct inhibition; the reported effect on tau may be downstream rather than a direct enzyme interaction

  Reduced tau hyperphosphorylation. In the triple-transgenic Alzheimer's mouse, chronic oral treatment reduced both tau and amyloid pathology alongside cognitive improvement.

Nothing acute, and nothing you will feel in the first week. Rodent benefits emerged over weeks to months of daily dosing, with the pivotal Alzheimer's study running chronic oral treatment over an extended period before cognitive and pathological outcomes separated. Anecdotal human protocols run 4-12 weeks for that reason. If anything is going to be detectable on a cognitive instrument, 8-12 weeks is the earliest reasonable point to look. No safe duration has been established and nobody has run it in a person for a year.

The Dihexa pairing is the one people run, on the reasoning that both aim at neurogenesis and synaptic repair through unrelated receptors. There is no data on the combination in either direction, and it is worth noting that P021's literature is intact while Dihexa's has been partly retracted - if you are choosing one neurogenesis compound, that difference is the argument. Stacking with Cerebrolysin is largely duplication, since Cerebrolysin's claimed activity explicitly includes CNTF-like fragments and P021 is a CNTF fragment analogue. The more coherent partner is something acting on a different axis entirely - Semax or FGL - though again with no combination data. The practical stacking note that matters most is temporal: P021 does nothing you can feel, so running it alongside anything stimulating means you will attribute the stimulant's effects to the peptide and learn nothing about either. If you want to evaluate P021, run it alone.

Against Dihexa, its closest peer: both were engineered for oral activity and blood-brain barrier penetration, both are rodent-only, and both are aimed at synaptic repair. The distinguishing fact as of 2025 is that P021's literature is intact while two of the foundational Dihexa mechanism papers have been retracted. P021 also lacks Dihexa's specific oncological concern - releasing a LIF brake on progenitor differentiation is not the same risk profile as potentiating c-Met - though a compound that manipulates progenitor-cell differentiation has never been evaluated in anyone with a malignancy. Against Cerebrolysin: Cerebrolysin has thousands of randomised patients and ambiguous results; P021 has clean rodent data and no humans. Those are different kinds of uncertainty and neither is reassuring. Against Semax or Selank: those you can feel and evaluate over a fortnight; P021 you cannot, which makes it a much harder compound to run rationally as an individual. Against davunetide, the other tau-directed peptide here: davunetide actually reached a large phase 3 trial and failed it, which is worth holding in mind when reading confident preclinical tau data on any compound.

$40–$150/month. A 10 mg vial typically runs 50-100 USD. At 500 mcg daily that is 20 days, so roughly 75-150 USD per month, and a full 12-week course is a meaningful expense for a compound with no human data. At the 250 mcg end it is closer to 40-70 USD per month. Availability is patchy and price varies more than for the mainstream compounds in this class.

• ?P021 has never entered a human trial. Every claim is rodent.
• ?No pharmacokinetic data exists in any species that I could locate - no tmax, half-life, bioavailability percentage, volume of distribution, clearance or protein binding.
• ?The LIF-inhibition mechanism is proposed by the developing group and has not been independently confirmed with a published binding or inhibition constant.
• ?Almost all the efficacy work comes from a single research lineage at the New York State Institute for Basic Research. Independent replication is essentially absent.
• ?The GSK-3beta effect on tau may be downstream rather than direct enzyme inhibition; the distinction has not been cleanly established.
• ?The anecdotal 250-1000 mcg human dose range is far below the allometric equivalent of the rodent efficacy dose and has no derivation I could trace.
• ?Whether the intranasal route offers any advantage over subcutaneous for this compound has never been compared.
• ?The molecular weight of 578.7 Da is plausible for the described structure but I did not verify it against a primary characterisation.
• ?No chronic safety data exists. The consequences of long-term manipulation of neural progenitor differentiation in an adult human are entirely unknown.

• Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K, Neurobiology of Disease, 2014 · PMID 25046994

  The pivotal P021 study. Chronic oral dosing in 3xTg-AD mice improved cognition and reduced both tau and amyloid pathology. Everything claimed for this compound traces here.

• Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome Kazim SF, Blanchard J, Bianchi R, Iqbal K, Scientific Reports, 2017 · PMID 28368015

  Extends the finding to a Down syndrome model with early-life dosing. Shows the compound's effects are developmental and structural rather than symptomatic.

• Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease Kazim SF, Iqbal K, Molecular Neurodegeneration, 2016 · PMID 27400746

  The review that situates P021 among neurotrophic mimetics generally, from the group that developed it. Useful for the design rationale, and read with the awareness that it is not an independent assessment.